European startups raised 12.3 billion in Q2 2025, signaling a cautious but real recovery - Silicon Canals

"The €12.3 billion figure, compiled from data tracked across major European venture databases and deal trackers, reveals a market that's concentrating capital rather than spraying it. Mega-rounds are returning - but only for companies with clear revenue trajectories and defensible technology. The spray-and-pray era of seed investing hasn't come back, and it probably shouldn't."

"This is the psychology of post-correction markets. Investors aren't less ambitious. They're more discriminating. And founders who survived the downturn are, almost by definition, the ones who figured out how to build something real under pressure. That survivor bias is now working in Europe's favor."

"The market isn't recovering to where it was. It's reorganizing around new priorities. Mega-rounds are returning - but only for companies with clear revenue trajectories and defensible technology. The spray-and-pray era of seed investing hasn't come back, and it probably shouldn't."

European startups secured €12.3 billion in Q2 2025 funding, marking a meaningful recovery from the subdued 2023-2024 period without returning to 2021 euphoria. This represents a market reorganization around new priorities rather than a simple recovery to previous conditions. Capital is concentrating selectively on companies with clear revenue trajectories and defensible technology, while spray-and-pray seed investing has not returned. Mega-rounds are emerging, but only for proven business models. Investors demonstrate increased discrimination rather than reduced ambition, and founders who survived the downturn possess survivor bias advantages. Health tech and life sciences sectors attract significant capital, driven by aging European populations and AI-driven advances in drug discovery and diagnostics.

Read at Silicon Canals